Orchard Therapeutics plc ORTX
At closeJan 23, 2024, 4:00 PM EST
52-week range unavailable
- Market cap
- 380.11M
- Revenue (ttm)
- 21.84M
- Shares out
- 22.76M
- Forward P/E
- -3.35
- Volume
- 372.35K
- Open
- 16.65
- Previous close
- 16.70
- Day's range
- 16.64 – 16.72
- Beta
- 0.55
- Analysts
- Hold
- Price target
- 16.00 (-4.2%)
- Earnings date
- Mar 4, 2024
3M +0.80 (+5.03%)
Key statistics
- Enterprise value
- 3.72B
- PEG ratio
- 0.00
- Price / sales
- 17.41
- Price / book
- 4.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 9.10%
- Free cash flow
- -49.64M
- Total cash
- 125.41M
- Total debt
- 47.82M
- Return on equity
- -71.50%
- Short % of float
- 0.15%
- 50-day average
- 16.44
- 200-day average
- 10.11
Analyst view
Consensus: hold
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 4, 2024
Expected Mar 4, 2024. Consensus EPS estimate -1.31.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2024 | Dec 1, 2023 | -2.10 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -1.30 | — | — | — |
| Aug 3, 2023 | Jun 1, 2023 | -1.67 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -1.78 | — | — | — |
| Mar 6, 2023 | Dec 1, 2022 | -1.80 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -2.30 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 4, 2023 | Stifel | down | Buy | Hold |
| Aug 8, 2023 | Oppenheimer | reit | Outperform | Outperform |
| Jun 26, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Jun 12, 2023 | Oppenheimer | main | Outperform | Outperform |
| Mar 27, 2023 | Cantor Fitzgerald | main | — | Overweight |
About Orchard Therapeutics plc
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- orchard-tx.com
News
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA 
Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel 
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome 
Orchard Therapeutics Announces Reimbursement Agreement in Spain 
Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD 
Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™ 
Orchard Therapeutics Announces Multiple Data Presentations and Publications 
Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries 
Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024 
Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day
Your note
Sign in to keep a note on ORTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FMR, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 4, 2021 | 0 |
| GASPAR BOBBY | Chief Executive Officer | Purchase | Mar 31, 2022 | 370,158 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 23, 2020 | 0 |
| THOMAS FRANK E | President | Conversion of Exercise of derivative security | Mar 9, 2023 | 92,081 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 8.99% | 2,041,670 | 10.64M | Jun 29, 2023 |
| Chi Advisors Llc | 3.33% | 755,738 | 3.94M | Jun 29, 2023 |
| Federated Hermes, Inc. | 2.24% | 508,222 | 2.65M | Jun 29, 2023 |
| Temasek Holdings (Private) Limited | 1.55% | 352,379 | 1.84M | Jun 29, 2023 |
| Deerfield Management Company, L.P. (Series C) | 1.39% | 316,169 | 1.65M | Jun 29, 2023 |
| Platinum Investment Management Ltd | 1.09% | 248,462 | 1.29M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 2,607 | 12.59K | May 30, 2023 |